I no longer believe it makes sense to sustain a bearish outlook on Teladoc, as its current valuation already reflects many negative aspects. At approximately 5x next year's free cash flow, Teladoc presents a better risk-reward profile than it has in quite some time. Teladoc's balance sheet, while not flawless, is manageable and can be improved with focused efforts.
Tech stocks got you down? While weeks of institutional tech stock outflows indicated souring sentiment, this week's tech sector “crash” — though due for a correction, considering its current concentration — only trades a few points below recent highs.
PURCHASE, NY, July 17, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release second quarter 2024 results on Wednesday, July 31, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation scenarios. The worldwide telehealth market was $122.2 billion in 2023 and is anticipated to rise 28.4% annually from 2024 to 2032.
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=90794&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 15, 2024 / If you suffered a loss on your Teladoc Health, Inc. (NYSE:TDOC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/teladoc-health-inc-lawsuit-submission-form?prid=90767&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Teladoc Health, Inc. (NYSE: TDOC) between November 2, 2022 and February 20, 2024, both dates inclusive (the “Class Period”), of the important July 16, 2024 lead plaintiff deadline.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.